NervGen Pharma Corp.
NGENF
$2.15
-$0.0182-0.84%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.30% | -20.58% | -20.68% | 4.31% | -3.98% |
| Total Depreciation and Amortization | -42.88% | -25.02% | -8.56% | 5.25% | 22.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.84% | 22.50% | 346.52% | 986.33% | 1,323.80% |
| Change in Net Operating Assets | 440.93% | -21.65% | 716.90% | -23.76% | -110.90% |
| Cash from Operations | -47.14% | -21.80% | 29.23% | 47.75% | 38.74% |
| Capital Expenditure | -- | 100.00% | 69.70% | 65.57% | 74.55% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.09% | 124.31% | -- | -- | -- |
| Cash from Investing | 141.16% | 123.77% | -1,965.96% | -923.30% | -527.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | -33.33% |
| Issuance of Common Stock | 2,716.70% | 2,316.22% | 15.39% | 4.33% | -96.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1,163.80% | -1,228.69% | -1,142.56% | -- |
| Cash from Financing | 2,861.01% | 2,812.73% | 4.85% | -5.39% | -96.73% |
| Foreign Exchange rate Adjustments | -139.54% | 97.89% | -47.73% | -131.24% | -117.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 154.49% | 149.46% | 110.62% | 115.30% | -286.79% |